UCB Ventures
UCB Ventures is an evergreen strategic corporate venture fund established in 2017. It makes long-term investments in early-stage companies developing novel therapeutic modalities and platforms in areas adjacent to UCB's therapeutic focus. The firm works closely with entrepreneurs to maximize patient value.
📥 Buy Full VC Dataset
Offices: Brussels (Belgium), London (United Kingdom), Boston (United States)
Investment Stages: Seed, Series A, Series B
Markets: Next-generation cell and gene therapy, regenerative medicine, cell and tissue homeostasis, RNA modulation, Oligo-based and synthetic biology therapeutics
Founded Year: 2017
Investor Type: Corporate VC
Portfolio Companies: Switch Therapeutics, Code Bio, SpliceBio, EsoBiotec, Neurona, Walden Biosciences, Rinri Therapeutics, ExeVir Bio, ViaNautis, Iris Medicine, Seamless, Syndesi Therapeutics, Ally Therapeutics, StrideBio, Locana
Website: https://www.ucbventures.com
Team Page: https://www.ucbventures.com/team
Portfolio Link: https://www.ucbventures.com/portfolio
LinkedIn: https://www.linkedin.com/company/ucb-ventures
Twitter: https://www.twitter.com/ucb_news
Crunchbase: https://www.crunchbase.com/organization/ucb-ventures
Comments
No comments yet. Be the first to comment!